ArticleGene therapy2008
A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting.
Article in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Article
- Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer.Cancer immunology, immunotherapy : CII · 2023Article
- Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus.Cancer gene therapy · 2022Article
- Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.Journal of virology · 2020Article
- Arming oncolytic reovirus with GM-CSF gene to enhance immunity.Cancer gene therapy · 2019Article
- Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer.Scientific reports · 2019Article
- Characterization of a replicating expanded tropism oncolytic reovirus carrying the adenovirus E4orf4 gene.Gene therapy · 2018Article
- Baculovirus-assisted Reovirus Infection in Monolayer and Spheroid Cultures of Glioma cells.Scientific reports · 2017Article
- Designing and building oncolytic viruses.Future virology · 2017Review
- Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.World journal of methodology · 2016Review
- Review
- Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.Viruses · 2015Review
- Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike.Gene therapy · 2015Article
- Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Human gene therapy · 2014Review
- Mammalian orthoreovirus T3D infects U-118 MG cell spheroids independent of junction adhesion molecule-A.Gene therapy · 2014Article
- Generation of genetically stable recombinant rotaviruses containing novel genome rearrangements and heterologous sequences by reverse genetics.Journal of virology · 2013Article
- Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.Cancer gene therapy · 2013Article
- Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.Journal of virology · 2012Article
- Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Orthoreovirus Type 3 Dearing is not pathogenic to humans and has been evaluated clinically as an oncolytic agent. Its transduction efficiency and the tumor cell selectivity may be enhanced by incorporating ligands for alternative receptors. However, the genetic modification of reoviruses has been difficult, and genetic targeting of reoviruses has not been reported so far. Here we describe a technique for generating genetically targeted reoviruses. The propagation of wild-type reoviruses on cells expressing a modified sigma 1-encoding segment embedded in a conventional RNA polymerase II transcript leads to substitution of the wild-type genome segment by the modified version. This technique was used for generating reoviruses that are genetically targeted to an artificial receptor expressed on U118MG cells. These cells lack the junction adhesion molecule-1 and therefore resist infection by wild-type reoviruses. The targeted reoviruses were engineered to carry the ligand for this receptor at the C terminus of the sigma 1 spike protein. This demonstrates that the C terminus of the sigma 1 protein is a suitable locale for the insertion of oligopeptide ligands and that targeting of reoviruses is feasible. The genetically targeted viruses can be propagated using the modified U118MG cells as helper cells. This technique may be applicable for the improvement of human reoviruses as oncolytic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.